Active Ingredient History
Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Arthritis, Juvenile (Phase 3)
Arthritis, Psoriatic (Phase 3)
Asthma (Phase 2)
Colitis, Ulcerative (Phase 3)
COVID-19 (Phase 2)
Crohn Disease (Phase 4)
Dermatitis (Phase 2)
Healthy Volunteers (Phase 1)
Hidradenitis Suppurativa (Phase 2)
HIV Infections (Phase 1)
Psoriasis (Phase 4)
Spondylitis, Ankylosing (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue